Antibody responses to influenza A(H1N1)pdm infection.
Antibodies
Hemagglutination inhibition
Influenza
Neuraminidase
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
02 06 2020
02 06 2020
Historique:
received:
10
01
2020
revised:
28
03
2020
accepted:
26
04
2020
pubmed:
12
5
2020
medline:
28
4
2021
entrez:
12
5
2020
Statut:
ppublish
Résumé
We investigated humoral immune response to influenza A(H1N1)pdm infection and found 32 (22%) of the infected individuals identified by PCR failed to produce a ≥ 4-fold hemagglutinin inhibition assay (HAI) response; a subset of 18 (56%) produced an alternate antibody response (against full-length HA, HA stalk, or neuraminidase). These individuals had lower pre-existing HAI antibody titers and showed a pattern of milder illness. An additional subset of 14 (44%) did not produce an alternate antibody response, had higher pre-existing antibody titers against full-length & stalk HA, and were less sick. These findings demonstrate that some individuals mount an alternate antibody response to influenza infection. In order to design more broadly protective influenza vaccines it may be useful to target these alternate sites. These findings support that there are influenza cases currently being missed by solely implementing HAI assays, resulting in an underestimation of the global burden of influenza infection.
Identifiants
pubmed: 32389495
pii: S0264-410X(20)30586-7
doi: 10.1016/j.vaccine.2020.04.069
pmc: PMC7707244
mid: NIHMS1592360
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4221-4225Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120997
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Infect Dis. 2018 Jul 2;218(3):347-354
pubmed: 29506129
Emerg Infect Dis. 2018 Oct;24(10):1882-1888
pubmed: 30226161
NPJ Vaccines. 2016;1:
pubmed: 29250435
J Infect Dis. 2019 Jan 9;219(3):347-357
pubmed: 30016464
Vaccine. 2009 Apr 21;27(18):2418-25
pubmed: 19368783
Nat Med. 2019 Jun;25(6):962-967
pubmed: 31160818
mBio. 2018 Apr 3;9(2):
pubmed: 29615508
mBio. 2017 Sep 19;8(5):
pubmed: 28928215
J Immunol. 2011 Apr 1;186(7):3823-9
pubmed: 21422252
J Infect Dis. 2013 Mar 15;207(6):974-81
pubmed: 23307936
PLoS Pathog. 2016 Jun 23;12(6):e1005692
pubmed: 27336297
Expert Rev Vaccines. 2013 May;12(5):519-36
pubmed: 23659300
Clin Vaccine Immunol. 2008 Jul;15(7):1042-53
pubmed: 18448618
PLoS Pathog. 2012;8(12):e1003061
pubmed: 23271967
J Virol. 2019 Apr 3;93(8):
pubmed: 30700610
Expert Rev Anti Infect Ther. 2011 Jun;9(6):669-83
pubmed: 21692672
J Thorac Dis. 2018 Jul;10(Suppl 19):S2238-S2247
pubmed: 30116603
Influenza Other Respir Viruses. 2018 Jan;12(1):3-9
pubmed: 29460425